Literature DB >> 7077331

Studies on the pyruvate dehydrogenase complex in brain with the arylamine acetyltransferase-coupled assay.

H Ksiezak-Reding, J P Blass, G E Gibson.   

Abstract

A spectrophotometric assay for the brain pyruvate dehydrogenase complex (PDHC) with arylamine acetyltransferase (ArAT; EC 2.3.1.5) to follow the production of acetyl-CoA has been standardized. Activity was proportional to time and protein. It depended completely on added pyruvate, CoA, NAD, and MgCl2, and partially on thiamine pyrophosphate. Triton X-100, and a sulfhydryl compound. The activities are the highest in the literature for brain PDHC (50 nmol/min/mg protein) and equal to maximum recorded rates of pyruvate flux for brain in vivo. Activities as low as 0.6 nmol/min could be measured. Use of ArAT at different purities (I--2-fold and II--55-fold) allowed convenient measurement of total PDHC (ArAT-I) and of the active form of PDHC (ArAT-II). The proportion of PDHC in the active form was 50% in mouse brain, 30% in brain, and 10% in mouse liver. Total PDHC activity was unchanged postmortem during storage of mouse brain in situ at +4 degrees C or at -20 degrees C for 3 days or at +20 degrees C for 24 h. The relative specific activity of PDHC in cytoplasmic or synaptoplasmic fractions was less than that of two other mitochondrial enzymes, fumarase (EC 4.2.1.2) and monoamine oxidase (EC 1.4.3.4), which argues strongly against the hypothesis of a cytoplasmic PDHC in cholinergic nerve endings.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7077331     DOI: 10.1111/j.1471-4159.1982.tb06643.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  11 in total

1.  Abnormalities in the tricarboxylic Acid cycle in Huntington disease and in a Huntington disease mouse model.

Authors:  Nima N Naseri; Hui Xu; Joseph Bonica; Jean Paul G Vonsattel; Etty P Cortes; Larry C Park; Jamshid Arjomand; Gary E Gibson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

2.  Immunocapture and microplate-based activity and quantity measurement of pyruvate dehydrogenase in human peripheral blood mononuclear cells.

Authors:  Xiaowen Liu; Hira Pervez; Lars W Andersen; Amy Uber; Sophia Montissol; Parth Patel; Michael W Donnino
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

3.  Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients.

Authors:  P Bubber; V Hartounian; G E Gibson; J P Blass
Journal:  Eur Neuropsychopharmacol       Date:  2010-11-30       Impact factor: 4.600

4.  Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease.

Authors:  R F Butterworth; A M Besnard
Journal:  Metab Brain Dis       Date:  1990-12       Impact factor: 3.584

Review 5.  Imaging brain activation: simple pictures of complex biology.

Authors:  Gerald A Dienel; Nancy F Cruz
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

6.  Activities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy: 1. The pyruvate dehydrogenase complex.

Authors:  R F Butterworth; J F Giguere; A M Besnard
Journal:  Neurochem Res       Date:  1985-10       Impact factor: 3.996

7.  Correlation of enzymatic, metabolic, and behavioral deficits in thiamin deficiency and its reversal.

Authors:  G E Gibson; H Ksiezak-Reding; K F Sheu; V Mykytyn; J P Blass
Journal:  Neurochem Res       Date:  1984-06       Impact factor: 3.996

8.  Mitochondrial enzymes in schizophrenia.

Authors:  Parvesh Bubber; Jicheng Tang; Vahram Haroutunian; Hui Xu; Kenneth L Davis; John P Blass; Gary E Gibson
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Regionally selective alterations in enzymatic activities and metabolic fluxes during thiamin deficiency.

Authors:  G Gibson; P Nielsen; V Mykytyn; K Carlson; J Blass
Journal:  Neurochem Res       Date:  1989-01       Impact factor: 3.996

10.  Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain.

Authors:  M Hoshi; A Takashima; K Noguchi; M Murayama; M Sato; S Kondo; Y Saitoh; K Ishiguro; T Hoshino; K Imahori
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.